Miami Dade Medical Research Institute | Miami, FL

Research site

Location

8955 SW 87th Court, Suite 112, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

MGL-3196

Bryostatin

DSC127

ITI-1284

AVP-786

Troriluzule

TRx0237

Orforglipron

BMS-986446

Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

14 of 56 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (EMBARQ-CSU1)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Active, not recruiting

Chronic Spontaneous Urticaria

Biological: barzolvolimab

Biological: Matching placebo

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Active, not recruiting

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting

NASH - Nonalcoholic Steatohepatitis

Procedure: Liver Biopsy

Drug: MGL-3196

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Active, not recruiting

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a...

Active, not recruiting

COVID-19

SARS-COV-2 Infection

Biological: Placebo

Biological: BNT162b2 Vaccine

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous...

Invitation-only

Chronic Spontaneous Urticaria

Biological: barzolvolimab

Other: Standard of Care

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling

Depressive Disorder, Major

Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Drug: Placebo

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Pe...

Active, not recruiting

Diabetic Foot Ulcers

Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with...

Enrolling

Generalized Anxiety Disorder

Drug: ITI-1284 10 mg

Drug: ITI-1284 20 mg

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy...

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: ITI-1284 10 mg

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder (GATE-251)

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel....

Enrolling

Major Depressive Disorder

Drug: Zelquistinel